# LYVE1

## Overview
LYVE1, or lymphatic vessel endothelial hyaluronan receptor 1, is a gene that encodes a transmembrane glycoprotein primarily expressed in lymphatic endothelial cells. This protein is a member of the Link protein superfamily and functions as a receptor for hyaluronan (HA), a key component of the extracellular matrix. LYVE1 plays a crucial role in the lymphatic system, particularly in the trafficking of immune cells such as dendritic cells and macrophages, as well as in maintaining endothelial cell function and permeability (Jackson2019Hyaluronan; Stanly2020The). The protein's interactions with HA and its involvement in signaling pathways, such as MAP kinase/Erk and Src non-receptor tyrosine kinase, underscore its importance in processes like lymphangiogenesis and immune response regulation (Jackson2019Hyaluronan). Additionally, LYVE1's expression and function have been linked to various pathological conditions, including cancer metastasis and Sturge-Weber syndrome, highlighting its clinical significance (Nasim2024MRC1; Jauch2022Lyve1).

## Structure
LYVE1, or lymphatic vessel endothelial hyaluronan receptor 1, is a type I integral membrane glycoprotein primarily expressed in lymphatic endothelial cells. It belongs to the Link protein superfamily and features a Link domain responsible for binding hyaluronan. This domain is crucial for its function in the lymphatic system. The protein structure of LYVE1 may undergo post-translational modifications, such as glycosylation, which can influence its stability and interactions. 

LYVE1 also has splice variant isoforms, which can affect its function and localization within the cell. These isoforms may result in variations in the protein's structure, potentially altering its binding capabilities and interactions with other cellular components. The presence of these isoforms suggests a level of regulatory complexity in the expression and function of LYVE1, allowing it to adapt to different physiological conditions. 

The specific details of LYVE1's primary, secondary, tertiary, and quaternary structures are not provided in the available context. However, the presence of the Link domain and potential glycosylation sites are significant features that contribute to its functional role in the lymphatic system.

## Function
LYVE1, or lymphatic vessel endothelial hyaluronan receptor 1, is a transmembrane glycoprotein primarily expressed in lymphatic endothelial cells. It functions as a receptor for hyaluronan (HA), a glycosaminoglycan present in the extracellular matrix, and plays a critical role in lymphatic endothelial cell function and immune cell trafficking (Jackson2019Hyaluronan; Stanly2020The).

In healthy human cells, LYVE1 is involved in the docking and migration of dendritic cells and macrophages across the lymphatic endothelium. This process is facilitated by the receptor's interaction with HA on the surface of these immune cells, enabling their transit through lymphatic capillaries to lymph nodes, which is essential for immune activation (Jackson2019Hyaluronan; Johnson2017Dendritic). The receptor's ability to bind HA is regulated by its clustering on the cell surface, which is influenced by the cortical actin network. This network restricts LYVE1's lateral mobility, and its disruption increases both LYVE1 diffusion and HA binding activity (Stanly2020The).

LYVE1 also plays a role in regulating endothelial permeability and cell proliferation through signaling pathways activated by its interaction with HA. These pathways include MAP kinase/Erk and Src non-receptor tyrosine kinase, which influence endothelial junctional integrity and cell proliferation (Jackson2019Hyaluronan). The receptor is also implicated in lymphangiogenesis, where it mediates the effects of degraded HA fragments, promoting lymphatic endothelial proliferation and migration (Jackson2019Hyaluronan).

## Clinical Significance
LYVE1 (lymphatic vessel endothelial hyaluronan receptor 1) has been implicated in various diseases and conditions due to alterations in its expression or interactions. In the context of cancer, LYVE1 expression is associated with the hepatic immune microenvironment and its role in liver metastasis. Studies have shown that LYVE1 deficiency can alter immune cell compositions in the liver, affecting susceptibility to melanoma liver metastasis. Specifically, LYVE1 deficiency leads to increased numbers of CD4+ and CD8+ T cells, regulatory T cells, and eosinophils, which may enhance anti-tumor immune responses and reduce melanoma metastasis (Jauch2022Lyve1).

In Sturge-Weber syndrome, a neurocutaneous disorder characterized by capillary malformations, LYVE1 is expressed by macrophages in the vascular beds affected by the GNAQ R183Q mutation. These macrophages, which also express MRC1 and CD68, are significantly increased in affected tissues and may contribute to the pathology of the syndrome through their interaction with the vascular environment. The presence of LYVE1+ macrophages is linked to pro-angiogenic signaling and inflammation, potentially influencing the formation and progression of capillary malformations in Sturge-Weber syndrome (Nasim2024MRC1).

## Interactions
LYVE1, a receptor primarily expressed in lymphatic endothelial cells, interacts with various proteins and participates in several signaling pathways. Although LYVE1 lacks endogenous catalytic activity, it may recruit kinase activity from growth factor receptors such as EGFR, PDGFR, and VEGFR. This is suggested by co-immunoprecipitation studies, indicating that LYVE1 can form complexes with these receptors to regulate endothelial junctional permeability and cell proliferation (Jackson2019Hyaluronan).

LYVE1's interaction with the actin cytoskeleton is characterized by its confinement within submembranous actin corrals, which restricts its lateral mobility. This interaction is not direct, as pull-down assays show minimal co-immunoprecipitation of actin with LYVE1, and experiments with cytoskeletal linker Ezrin do not indicate indirect interaction via ERM proteins (Stanly2020The). Despite this, LYVE1's mobility is limited by transient entrapment within the actin meshwork, consistent with the picket-fence model (Stanly2020The).

LYVE1 also interacts with hyaluronan (HA), a glycosaminoglycan, to activate signaling pathways such as the MAP kinase/Erk and Src non-receptor tyrosine kinase pathways. These interactions lead to the phosphorylation of VE-cadherin, affecting junctional integrity (Jackson2019Hyaluronan).


## References


[1. (Johnson2017Dendritic) Louise A Johnson, Suneale Banerji, William Lawrance, Uzi Gileadi, Gennaro Prota, Kayla A Holder, Yaowaluck M Roshorm, Tomáš Hanke, Vincenzo Cerundolo, Nicholas W Gale, and David G Jackson. Dendritic cells enter lymph vessels by hyaluronan-mediated docking to the endothelial receptor lyve-1. Nature Immunology, 18(7):762–770, May 2017. URL: http://dx.doi.org/10.1038/ni.3750, doi:10.1038/ni.3750. This article has 145 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/ni.3750)

[2. (Jackson2019Hyaluronan) David G. Jackson. Hyaluronan in the lymphatics: the key role of the hyaluronan receptor lyve-1 in leucocyte trafficking. Matrix Biology, 78–79:219–235, May 2019. URL: http://dx.doi.org/10.1016/j.matbio.2018.02.001, doi:10.1016/j.matbio.2018.02.001. This article has 101 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1016/j.matbio.2018.02.001)

[3. (Jauch2022Lyve1) Anna Sophia Jauch, Sebastian A. Wohlfeil, Céline Weller, Bianca Dietsch, Verena Häfele, Ana Stojanovic, Maximilian Kittel, Hendrik Nolte, Adelheid Cerwenka, Michael Neumaier, Kai Schledzewski, Carsten Sticht, Philipp-Sebastian Reiners-Koch, Sergij Goerdt, and Cyrill Géraud. Lyve-1 deficiency enhances the hepatic immune microenvironment entailing altered susceptibility to melanoma liver metastasis. Cancer Cell International, December 2022. URL: http://dx.doi.org/10.1186/s12935-022-02800-x, doi:10.1186/s12935-022-02800-x. This article has 10 citations and is from a peer-reviewed journal.](https://doi.org/10.1186/s12935-022-02800-x)

[4. (Nasim2024MRC1) Sana Nasim, Colette Bichsel, Stephen Dayneka, Robert Mannix, Annegret Holm, Mathew Vivero, Sanda Alexandrescu, Anna Pinto, Arin K. Greene, Donald E. Ingber, and Joyce Bischoff. Mrc1 and lyve1 expressing macrophages in vascular beds of gnaq p.r183q driven capillary malformations in sturge weber syndrome. Acta Neuropathologica Communications, March 2024. URL: http://dx.doi.org/10.1186/s40478-024-01757-4, doi:10.1186/s40478-024-01757-4. This article has 1 citations and is from a peer-reviewed journal.](https://doi.org/10.1186/s40478-024-01757-4)

[5. (Stanly2020The) Tess A. Stanly, Marco Fritzsche, Suneale Banerji, Dilip Shrestha, Falk Schneider, Christian Eggeling, and David G. Jackson. The cortical actin network regulates avidity-dependent binding of hyaluronan by the lymphatic vessel endothelial receptor lyve-1. Journal of Biological Chemistry, 295(15):5036–5050, April 2020. URL: http://dx.doi.org/10.1074/jbc.ra119.011992, doi:10.1074/jbc.ra119.011992. This article has 16 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1074/jbc.ra119.011992)